• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    4/8/24 8:09:45 AM ET
    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their outstanding shares is at $9.6 million.
    • PetVivo Hldgs (NASDAQ:PETV) stock increased by 17.09% to $1.22. The company's market cap stands at $20.4 million.
    • SHL Telemedicine (NASDAQ:SHLT) stock moved upwards by 13.26% to $6.49. The company's market cap stands at $106.3 million.
    • Pluri (NASDAQ:PLUR) stock moved upwards by 12.02% to $6.15. The market value of their outstanding shares is at $32.1 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 11.35% to $0.5. The company's market cap stands at $8.8 million.
    • Ocugen (NASDAQ:OCGN) stock moved upwards by 8.19% to $1.98. The company's market cap stands at $508.0 million. As per the press release, Q4 earnings came out 4 days ago.

    Losers

    • BioRestorative Therapies (NASDAQ:BRTX) stock fell 18.8% to $1.08 during Monday's pre-market session. The company's market cap stands at $7.3 million.
    • Supernus Pharmaceuticals (NASDAQ:SUPN) stock fell 16.34% to $28.07. The company's market cap stands at $1.5 billion.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) stock fell 11.32% to $3.45. The market value of their outstanding shares is at $4.0 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) stock fell 11.21% to $1.03. The market value of their outstanding shares is at $1.7 million.
    • G1 Therapeutics (NASDAQ:GTHX) shares declined by 10.33% to $4.29. The market value of their outstanding shares is at $223.7 million.
    • GlucoTrack (NASDAQ:GCTK) shares decreased by 9.81% to $0.45. The company's market cap stands at $12.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $BRTX
    $GCTK
    $GTHX

    CompanyDatePrice TargetRatingAnalyst
    Supernus Pharmaceuticals Inc.
    $SUPN
    10/9/2025$65.00Neutral → Overweight
    Piper Sandler
    Supernus Pharmaceuticals Inc.
    $SUPN
    7/30/2025$42.00Neutral → Overweight
    Cantor Fitzgerald
    Supernus Pharmaceuticals Inc.
    $SUPN
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    Supernus Pharmaceuticals Inc.
    $SUPN
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Ocugen Inc.
    $OCGN
    10/15/2024$4.00Buy
    Maxim Group
    Supernus Pharmaceuticals Inc.
    $SUPN
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 4:31:16 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 11:21:53 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 12, 2021 - FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy

    For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi

    2/12/21 5:24:11 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO Khattar Jack A. converted options into 38,640 shares and covered exercise/tax liability with 16,574 shares, increasing direct ownership by 2% to 1,228,644 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/10/26 4:13:50 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Tech. Ops. Officer Mottola Frank converted options into 3,750 shares, covered exercise/tax liability with 1,793 shares and sold $87,074 worth of shares (1,623 units at $53.65), increasing direct ownership by 2% to 18,440 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/10/26 4:13:22 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior Vice-President & CFO Dec Timothy C converted options into 6,000 shares and covered exercise/tax liability with 2,883 shares, increasing direct ownership by 61% to 8,232 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/10/26 4:12:53 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner A.L. Sarroff Fund, Llc converted options into 974,809 shares and bought $77,999 worth of shares (154,840 units at $0.50) (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:39 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc bought $485,355 worth of shares (718,358 units at $0.68) and converted options into 4,033,209 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:14 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc converted options into 164,340 shares and bought $100,001 worth of shares (111,112 units at $0.90) (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:37:39 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Supernus Pharma upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $65.00

    10/9/25 8:22:44 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $42.00

    7/30/25 7:19:36 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

    2/19/25 7:05:55 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron Announces Private Placement of up to $30 Million

    $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,

    3/10/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

    RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA '26 Summit, taking place March 16-20, 2026, in Dana Point, California. The presentation will take place on Tuesday, March 17 at 8:15 a.m. PT. Dr. Goode will introduce Glucotrack's continuous blood glucose monitor (CBGM) technology, share its positive first-in-human study results, outline the Company's regulatory strategy and commercialization

    3/10/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

    GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bri

    3/6/26 8:00:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    SEC Filings

    View All

    SEC Form 144 filed by Supernus Pharmaceuticals Inc.

    144 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    3/9/26 4:43:35 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Supernus Pharmaceuticals Inc.

    144 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    3/6/26 4:24:54 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/6/26 8:15:35 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Financials

    Live finance-specific insights

    View All

    Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

    Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™. Cash, cash equivalents and current marketable securities were $308.7 million at December 31, 2025. New patient initiation for ONAPGO resumed in the first quarter of 2026. Full

    2/24/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026

    MINNEAPOLIS, MN, US, Feb. 17, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTC ID: PETVW)), and its wholly owned subsidiaries PetVivo Animal Health and PetVivo AI, a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported financial and operational results for the third quarter and first nine months of its fiscal year 2026 ended December 31, 2025. The company will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q3 Operational Highlights Signed an exclusive 10-ye

    2/17/26 4:30:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $ADIL
    $BRTX
    $GCTK
    $GTHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/14/24 5:14:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care